Actively Recruiting
Genetics of Central Nervous System Arteriovenous Malformations (GENE-MAV)
Led by Fondation Ophtalmologique Adolphe de Rothschild · Updated on 2026-01-22
300
Participants Needed
1
Research Sites
262 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cerebral and medullary arteriovenous malformations (AVMs) lead to arterial and venous networks to communicate pathologically, creating an arteriovenous shunt. The occurrence of intracranial haemorrhage is the most important prognostic factor of AVMs because it is associated with a significant morbidity and mortality. The genetic, molecular and cellular mechanisms that cause vascular malformations of the central nervous system are partially known and the influence of genetic damage on the prognosis of AVMs is poorly known.
CONDITIONS
Official Title
Genetics of Central Nervous System Arteriovenous Malformations (GENE-MAV)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with a vascular malformation of the cerebral or medullary identified on diagnostic imaging (angio-CT, angio-MRI or diagnostic angiography) for which clinical monitoring alone or intervention (endovascular treatment, surgery or radiosurgery) is planned in the centres participating in the research.
You will not qualify if you...
- Pregnant, parturient or breastfeeding woman
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
HOPITAL FONDATION Adolphe de ROTHSCHILD
Paris, France, 75019
Actively Recruiting
Research Team
S
Stanislas Smajda, MD
CONTACT
A
Amélie Yavchitz, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here